Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia

a technology of cannabidivarin and autism spectrum disorder, applied in the field of use, can solve the problems of not being fully manifested, unfavorable to adapt to tone and content, and react unusually negatively, and achieve the effect of improving symptoms

Inactive Publication Date: 2019-03-07
GW RES LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0120]In a further embodiment the CBDV may be used as a dietary supplement or food add

Problems solved by technology

When responding to others, school age children with ASD often take people's speech literally and are unable to understand sarcasm, metaphors or figures of speech they may also react unusually negatively when asked to do something by someone else.
When interacting with others school age children with ASD may not be aware of other people's personal space, or are unusually intolerant of people entering their own personal space; show little interest in interacting with other people, including children of a similar age, or have few close friends, despite attempts to form friendships; not understand how people normally interact socially, such as greeting people or wishing them farewell; are unable to adapt the tone and content of their speech to different social situations for example, speaking very formally at a party and then speaking to total strangers in a familiar way; not enjoy situations and activities that most children of their age enjoy; rarely use gestures or facial expressions when communicating; and avoid eye contact.
Symptoms must be present in early childhood but may not become fully manifest until social demands exceed limited capacities.D.
Symptoms together limit and impair everyday functioning.
The instability is caused by an excess of genetic code in this region.
The social impairments associated with FXS often increase as the patient gets older.
Speech may be cluttered or nervous.
There is currently no drug treatment that has shown benefit specifically for FXS.
Typically, development appears to be normal in the first six to eighteen months but this is followed by a period of regression resulting in a loss of language and motor skills, leading to severe or profound learning and physical disabilities.
The symptoms include: a general slowness in development; hypertonia; difficulty feeding; abnormal hand movements; lack of interest in toys; and poor coordination of trunk and limbs.
Problems arise with communication, language, learning, co-ordination and brain functions.
Signs at this stage include: repetitive and uncontrollable hand movements; periods of distress, irritability and screaming; social withdrawal; unsteadiness when walking; rapid or slow breathing; problems sleeping; small head size; difficulty eating and gastrointestinal p

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia
  • Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia
  • Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia

Examples

Experimental program
Comparison scheme
Effect test

example 1

nnabidivarin (CBDV) in a Mouse Model of Autism Spectrum Disorder

[0170]The phytocannabinoid cannabidivarin (CBDV) was evaluated in a rodent model of autism spectrum disorder (ASD).

[0171]In utero exposure of rodents to valproic acid (VPA) has been shown to induce a phenotype with behavioural characteristics similar to those observed in ASD and provides a robust animal model for social cognitive impairment understanding and a potential screen for the development of novel therapeutics for this condition (Foley et al. 2012).

[0172]Thus, in utero exposure to VPA has been used as a reliable model to increase the understanding of behavioural effects evaluated by specific tests as sociability, social preference and stereotypic behaviour, also observed in human patients (Schneider and Przewlocki, 2005).

[0173]Example 1 describes the use of prenatal VPA exposure in rats to evaluate the efficacy of chronic CBDV administration in reversing the autism-like behaviours present in this model.

Materials...

example 2

nnabidivarin (CBDV) in a Mouse Model of Fragile X Syndrome

[0201]The phytocannabinoid cannabidivarin (CBDV) was evaluated in a mouse model of Fragile X syndrome (FXS). Such model evaluates the treatment on cognitive deficits and seizures present in Fmr1 knockout (KO) mice.

Materials and Methods

Animals

[0202]Fmr1 KO mice and wild type mice were obtained and housed four per cage in a temperature of 21° C.±1° C. and humidity of 55%±10% controlled environment. Food and water were available ad libitum. All experiments were performed during the light phase of a 12 hour light / dark cycle (08:00 to 20:00). Animals were handled for one week before the start of experiments. All behavioural tests were performed by researchers blind to the different experimental groups.

Novel Object Recognition Task

[0203]On day one mice were habituated for 10 minutes to the empty V-maze in which the task was to be performed. On the second day the mice went back to the maze for 10 minutes which contained two identica...

example 3

nnabidivarin (CBDV) in a Mouse Model of Rett Syndrome

[0215]The phytocannabinoid cannabidivarin (CBDV) was evaluated in a mouse model of Rett syndrome (RS). Such model evaluates the treatment on motor alterations and cognitive deficits present in MeCP2 KO mice.

[0216]CBDV was administered daily at the dose of 2, 20 and 200 mg / kg i.p. starting from PND 28 and the following signs were scored every other day: hindlimb clasping (indication of motor imbalance), tremor, gait (measure of coordination), breathing, mobility and general condition.

[0217]Furthermore, the efficacy of CBDV in reverting / attenuating the short- and long-term memory deficits present in these mice was evaluated. The Novel Object Recognition (NOR) test was performed before the starting of the treatment Post Natal Day 28 (PND 28), at PND 41 when the first motor symptoms appear and at PND 56 and 66 when the disease is fully manifested.

Materials and Methods

[0218]The CBDV was dissolved in ethanol, cremophor and saline (1:1:1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.

Description

[0001]This application is a continuation application of International Application No. PCT / GB2017 / 051007, filed on Apr. 11, 2017, which claims the benefit of priority of British Patent Application No. GB 1606098.0, filed on Apr. 11, 2016. The contents of these applications are each incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia.[0003]CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia.[0004]The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/05A61P25/18A61P25/28
CPCA61K31/05A61P25/18A61P25/28A61K45/06A61K31/352A61K36/185A61K36/00G01N33/6896A61P25/00A61P25/14
Inventor GUY, GEOFFREYWRIGHT, STEPHENBRODIE, JAMESWOOLLEY-ROBERTS, MARIEMALDONADO, RAFAELPAROLARO, DANIELALUONGO, LIVIONEILL, JOANNA
Owner GW RES LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap